TABLE OF CONTENTS

CONFERENCE PRESENTATIONS i

ACKNOWLEDGEMENTS ii

ABSTRACT iv

TABLE OF CONTENTS vi

LIST OF TABLES xii

LIST OF FIGURES xvii

ABBREVIATIONS xxi

CHAPTER 1 INTRODUCTION

1.1 ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS 1

1.1.1 Mechanism of action 2

1.1.2 Chemical features of ACE inhibitors 5

1.2 CLINICAL USES OF ACE INHIBITORS 6

1.2.1 Hypertension 6

1.2.2 Congestive Heart Failure (CHF) 7

1.3 THE USE OF CAPTOPRIL FOR THE TREATMENT OF HYPERTENSION AND CONGESTIVE HEART FAILURE 9

1.3.1 General characteristics 9

1.3.2 Dosage and Administration 10

1.4 PHARMACOKINETICS OF CAPTOPRIL 11

1.4.1 Absorption 11

1.4.1.1 Effect of food 13

1.4.1.2 Effect of age 14

1.4.1.3 Gender effect 14

1.4.2 Distribution 14

1.4.3 Metabolism and excretion 16

1.4.4 Clearance 18

1.4.5 Elimination half life 19

1.5 PHARMACOKINETICS OF CAPTOPRIL IN PATIENTS WITH HYPERTENSION AND CONGESTIVE HEART FAILURE 20

1.5.1 Hypertension 20

1.5.2 Congestive heart failure 21

1.6 ADVERSE EFFECTS OF CAPTOPRIL 23

1.7 AIM OF THE PRESENT STUDY 24

1.8 POSSIBLE OUTCOMES OF THE STUDY 25

CHAPTER 2 ANALYTICAL METHODOLOGY FOR CAPTOPRIL 27

2.1 INTRODUCTION 27

2.1.1 The existence of a sulphydryl group in the captopril structure 27

2.1.2 Chemical structure for the detection of captopril by GCMS 28

2.1.3 Internal standard 28

2.2 PUBLISHED METHODS FOR CAPTOPRIL ANALYSIS 30

2.2.1 High performance liquid chromatography 30

2.2.2 Gas chromatography-mass spectrometry 32

2.3 METHOD DEVELOPMENT FOR CAPTOPRIL FOR THE PRESENT STUDY 33

2.3.1 Introduction 33

2.3.2 Extraction method of captopril 40

2.4 EXPERIMENTAL 43

2.4.1 Chemicals 43

2.4.2 Stock solutions 43

2.4.3 Standard / control solutions 43

2.4.4 Sample preparation 43

2.4.5 Gas Chromatograph – Mass Spectrometer 44

2.4.6 Method validation for the captopril assay 45

2.4.6.1 Specificity 45

2.4.6.2 Calibration curve 45

2.4.6.3 Precision, accuracy and recovery 46

2.4.6.4 Stability 47

2.5 RESULT AND DISCUSSION 48

2.6 CONCLUSION 58

CHAPTER 3 BIOEQUIVALENCE STUDY OF 4 BRANDS OF GENERIC CAPTOPRIL 59

3.1 INTRODUCTION 59

3.1.1 The concept of Bioequivalence 59

3.1.2 Bioavailability 61

3.1.3. Requirement for bioequivalence 61

3.1.4 Design of bioequivalence study 62

3.1.4.1 Parallel-Groups design 62

3.1.4.2 Two Period Crossover Design 63

3.1.4.3 Subjects and number of subject 63

3.1.5 Relevant pharmacokinetic parameters 64

3.1.6 Statistical analysis 66

3.2 STUDY OBJECTIVES 69

3.2.1 Primary Objective 69

3.2.2 Secondary Objective 69

3.3 STUDY TREATMENTS 69

3.3.1 Reference (R) 69

3.3.2 Test (T) 70

3.4 FACILITIES 71

3.5 STUDY METHODS 71

3.5.1 Study Design 71

3.5.2 Subject Number 72

3.5.3 Subject Enrolment 72

3.5.4 Restriction 74

3.5.5 Drug Accountability and Dosing 74

3.5.6 Admission and Procedure 75

3.5.7 Blood Sampling 77

3.5.8 Washout Period 79

3.6 ANALYTICAL METHOD 80

3.7 PHARMACOKINETICS AND STATISTICAL EVALUATION 81

3.7.1 Pharmacokinetics 81

3.7.2 Statistical 82

3.8 CLINICAL AND SAFETY RECORDS 82

3.9 DATA AND SAMPLES 83

3.10 GOOD CLINICAL PRACTICE AND ETHICAL CONSIDERATION 84

3.10.1 Ethics Approval 84

3.10.2 Informed Consent 84

3.10.3 Volunteer Compensation 85

3.10.4 Termination of the Study 85

3.10.5 Confidentiality 85

3.11 INTERIM ANALYSIS 85

3.12 RESULTS AND DISCUSSION 85

3.13 CONCLUSIONS 131

CHAPTER 4 POPULATION ANALYSIS OF PHARMACOKINETIC PARAMETERS OF CAPTOPRIL 132

4.1 INTRODUCTION 132

4.2 METHOD 133

4.3 RESULT 135

4.4 DISCUSSION AND CONCLUSION 144

CHAPTER 5 GENERAL CONCLUSION 145

REFERENCES 150

APPENDICES 163